Last Updated : November 6, 2023
Details
FilesProject Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Rapid Review
Project Number:
RC1510-000
Question
- What are the evidence-based guidelines regarding the use of anti-VEGF drugs for adult patients with suspected or confirmed wet AMD?
Key Message
Wet age-related macular degeneration (AMD) is a serious health concern that causes reduced vision-related function, poor overall quality of life, and increased health care resource usage. Antivascular endothelial growth factor (VEGF) drugs are the first-line treatment for wet AMD, and they are injected into the eye. These drugs can slow disease progression but are expensive and require trained medical professionals to administer and monitor treatment response. The criteria for initial injection, maintenance, and discontinuation of anti-VEGF drugs in patients with wet AMD remain unclear.
Files
Last Updated : November 6, 2023